The studies meta-analyzed data from spinal fusion surgeries that used iiliac crest bone grafts as well as data from Medtronic on patients treated with Infuse.
While the Medtronic product appeared similarly effective to iliac crest bone grafts, both pain and cancer were more commonly reported after the use of Infuse.
Both studies concluded that while Infuse is comparably effective to an iliac crest bone graft, it is correlated with adverse outcomes such as little pain reduction and cancer at higher rates post-surgery.
The studies were funded by Yale University and Medtronic. For the North American Spine Society response to the studies, click here.
More Articles on Spine
Medtronic Files to Dismiss Whistleblower Lawsuit
New Technologies to Make Spine Surgery Safer: Q&A With Dr. William Sonstein
Medtronic Receives CE Mark, Initiates European Launch of Spinal Deformity Instrument
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.